Oncotarget

Research Papers:

Translation initiation complex eIF4F is a therapeutic target for dual mTOR kinase inhibitors in non-Hodgkin lymphoma

Christos Demosthenous, Jing Jing Han, Mary J. Stenson, Matthew J. Maurer, Linda E. Wellik, Brian Link, Kristen Hege, Ahmet Dogan, Eduardo Sotomayor, Thomas Witzig and Mamta Gupta _

PDF  |  HTML  |  Supplementary Files  |  Order a Reprint

Oncotarget. 2015; 6:9488-9501. https://doi.org/10.18632/oncotarget.3378

Metrics: PDF 1332 views  |   HTML 1036 views  |   ?  


Abstract

Christos Demosthenous1,*, Jing Jing Han1,*, Mary J. Stenson1, Matthew J. Maurer1, Linda E. Wellik1, Brian Link2, Kristen Hege3, Ahmet Dogan4, Eduardo Sotomayor5, Thomas Witzig1, Mamta Gupta1

1Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA

2Department of Internal Medicine, University of Iowa College of Medicine, IA, USA

3Celgene Corporation, San Francisco, CA, USA

4Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA

5Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL, USA

*These authors have contributed equally to this work

Correspondence to:

Mamta Gupta, e-mail: gupta.mamta@mayo.edu

Keywords: translation initiation complex, eIF4E, lymphoma, dual mTOR inhibitors, CC214-1

Received: February 11, 2015     Accepted: February 12, 2015     Published: March 20, 2015

ABSTRACT

Deregulated mRNA translation has been implicated in disease development and in part is controlled by a eukaryotic initiation complex eIF4F (composed of eIF4E, eIF4G and eIF4A). We demonstrate here that the cap bound fraction from lymphoma cells was enriched with eIF4G and eIF4E indicating that lymphoma cells exist in an activated translational state. Moreover, 77% (110/142) of diffuse large B cell lymphoma tumors expressed eIF4E and this was associated with an inferior event free survival. Over-expression of wild-type eIF4E (eIF4EWT) but not cap-mutant eIF4E (eIF4Ecap mutant) increased the activation of the eIF4F complex. Treatment with the active-site dual mTOR inhibitor CC214-1 reduced the level of the eIF4F complex by decreasing the cap bound fraction of eIF4G and increasing the levels of 4E-BP1. CC214-1 inhibited both the cap dependent and global protein translation. CC214-1 inhibited c-Myc, and cyclin D3 translation by decreasing polysomal fractions from lymphoma cells. Inhibition of eIF4E with shRNA further decreased the CC214-1 induced inhibition of the eIF4F complex, c-Myc, cyclin D3 translation, and colony formation. These studies demonstrate that the eIF4F complex is deregulated in aggressive lymphoma and that dual mTOR therapy has therapeutic potential in these patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 3378